DB
RARE icon

Danske Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

Danske Bank’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.34K Hold
100
– – ﹤0.01% 955
2026
Q1 		$2.1K Sell
100
-1,200
-92% -$27K ﹤0.01% 993
2025
Q4 		$29.9K Hold
1,300
– – ﹤0.01% 1116
2025
Q3 		$39.1K Hold
1,300
– – ﹤0.01% 1065
2025
Q2 		$47.3K Buy
1,300
+1,200
+1,200% +$43.3K ﹤0.01% 1046
2025
Q1 		$3.62K Hold
100
– – ﹤0.01% 1202
2024
Q4 		$4.21K Sell
100
-1,500
-94% -$74.4K ﹤0.01% 1213
2024
Q3 		$88.9K Buy
+1,600
New +$81.5K ﹤0.01% 1040

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Danske Bank's RARE Position: Q2 2026 in Review

Danske Bank held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 100 shares worth $3.34K. The position accounts for ﹤0.01% of the portfolio, ranked #955.

Danske Bank first reported a position in RARE in Q3 2024 and has held it in 8 quarters since. The position peaked at $88.9K in Q3 2024. 206 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Danske Bank held 100 shares of Ultragenyx Pharmaceutical worth $3.34K as of Q2 2026.
  • Danske Bank left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #955 holding.
  • Danske Bank first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
  • Danske Bank's Ultragenyx Pharmaceutical position peaked at $88.9K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.